What is the domestic price of erdafitinib? Current market price and purchase method

Erdafitinib is an FGFR (fibroblast growth factor receptor) inhibitor primarily used to treat advanced or metastatic urothelial carcinoma harboring FGFR2 or FGFR3 mutations. The drug can inhibit the FGFR signaling pathway and prevent the growth and spread of cancer cells. It is the first oral targeted drug approved for bladder cancer. In China, erdafitinib has been on the market, but due to its short time on the market, it has not yet been included in medical insurance, and purchase channels are relatively limited.

Since the supply in the domestic market is still unstable, patients may consider overseas drug purchase channels. Currently, Erdafitinib's original brand drug Hong Kong version is sold at a higher price. Each box costs about more than 20,000 yuan. It needs to be purchased through Hong Kong pharmacies . This channel is relatively formal, and the quality of the drugs is guaranteed, but the price is relatively expensive, and purchase may require a doctor's prescription or relevant certificates.

For patients with limited financial conditions, they can choose foreign generic drugs The prices are relatively affordable. At present, generic drugs of erdafitinib are mainly sourced from Laos and Yaopin International of Bangladesh, and their selling prices range from a few hundred yuan to more than 2,000 yuan. The active ingredients of these generic drugs are basically the same as the original drugs, but there may be certain differences in efficacy, bioequivalence and safety. Patients are advised to choose carefully under the guidance of a doctor.

Considering the safety and accessibility of purchasing drugs, patients can pay attention to regular overseas drug purchasing platforms to avoid purchasing counterfeit drugs through informal channels. In addition, with the promotion of erdafitinib in China, there may be charity drug donations and patient assistance programs in the future. Patients can pay attention to the latest policy developments to reduce the financial burden and obtain more stable treatment options.